急性髓系白血病中吉妥珠单抗奥唑米星的突变谱与获益
该回顾性研究探讨分子事件对初治急性髓系白血病(AML)患者标准一线化疗联合吉妥珠单抗奥唑米星(GO)获益的预测价值。按ELN 2017风险分类,GO获益限于预后良好(HR 0.54,95%CI 0.30-0.98)和中危(HR 0.57,95%CI 0.33-1.00)组,不良风险组无获益(HR 0.93,95%CI 0.61-1.43)。携带激活信号突变患者GO获益显著(HR 0.43,95%CI 0.28-0.65),且与较高CD33表达相关。
要点
- GO联合标准一线化疗的获益限于ELN 2017预后良好和中危组,不良风险组无获益。
- 激活信号突变患者从GO联合治疗中显著获益,且与较高CD33表达水平相关。
- 分子异常可能用于预测GO获益并指导基于整合遗传谱的差异化治疗。
核心结论
- GO联合标准一线化疗的获益限于ELN 2017预后良好和中危风险组,不良风险组无获益。
- 携带激活信号突变的患者GO获益显著,且该获益与较高CD33表达水平相关。
- 分子异常可能对未来基于整合遗传谱的差异化治疗具有关键预测价值。
研究设计与样本
- 回顾性研究,评估分子事件对初治AML患者标准一线化疗联合GO获益的预测价值。
- 采用欧洲白血病网(ELN)2017风险分类进行风险分层分析。
主要发现
- GO获益在预后良好组HR 0.54(95%CI 0.30-0.98),中危组HR 0.57(95%CI 0.33-1.00)。
- 不良风险组GO对结局无影响,HR 0.93(95%CI 0.61-1.43)。
- 激活信号突变患者GO获益显著,HR 0.43(95%CI 0.28-0.65),并与较高CD33表达相关。
关键数值与推荐
- 预后良好组GO获益HR 0.54(95%CI 0.30-0.98)。
- 中危组GO获益HR 0.57(95%CI 0.33-1.00)。
- 不良风险组GO获益HR 0.93(95%CI 0.61-1.43)。
- 激活信号突变患者GO获益HR 0.43(95%CI 0.28-0.65)。
临床怎么用
- 可依据ELN 2017风险分类评估GO联合标准一线化疗的适用人群。
- 携带激活信号突变且CD33表达较高的AML患者可能优先从GO联合治疗中获益。
局限性
- 本研究为回顾性分析,结论需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukemia (AML) is a highly heterogeneous disease both in terms of genetic background and response to chemotherapy. Although molecular aberrations are routinely used to stratify AML patients into prognostic subgroups when receiving standard chemotherapy, the predictive value of the genetic background and co-occurring mutations remains to be assessed when using newly approved antileukemic drugs. In the present study, we retrospectively addressed the question of the predictive value of molecular events on the benefit of the addition of gemtuzumab ozogamicin (GO) to standard front-line chemotherapy. Using the more recent European LeukemiaNet (ELN) 2017 risk classification, we confirmed that the benefit of GO was restricted to the favorable (hazard ratio [HR], 0.54, 95% confidence interval [CI], 0.30-0.98) and intermediate (HR, 0.57; 95% CI, 0.33-1.00) risk categories, whereas it did not influence the outcome of patients within the adverse risk subgroup (HR, 0.93; 95% CI, 0.61-1.43). Interestingly, the benefit of GO was significant for patients with activating signaling mutations (HR, 0.43; 95% CI, 0.28-0.65), which correlated with higher CD33 expression levels. These results suggest that molecular aberrations could be critical for future differentially tailored treatments based on integrated genetic profiles that are able to predict the benefit of GO on outcome.
引用
- Fournier E, Duployez N, Ducourneau B, et al. Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia. Blood. 2020. PMID: 31880804. doi:10.1182/blood.2019003471
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。